Uniphar

FY 21: 30% EBITDA growth, excellent FCF

  • Sectors : Pharma and healthcare
  • Companies : Uniphar

Ratings and price correct at time of issue.

  • Uniphar

    Closing Price: 400c

  • RATING 27/08/19

  • PREVIOUS RATING N/A

DAVY VIEW

Uniphar continues to build on its excellent track record of high growth, high quality earnings and strong free cash flow (FCF). For FY 21, it has delivered over 8% organic gross profit growth and EBITDA ‘in-line’ with expectations (consensus €86.5m, +30% yoy). Better FCF conversion will also result in net debt coming in lower than forecast. We remind investors that Uniphar set a target at IPO of doubling EBITDA within five years. It is now on track to do this within three to four years, which is an incredible result. We reiterate our ‘Outperform’ rating and €5.0 price target.

Download full report with analyst certification and important disclosures

Jan 26 2022, 07:15 GMT

Download